Topic: rheumatoid arthritis
AbbVie investors were relieved when the company announced first-quarter results that exceeded forecasts, driven largely by an increase in Humira sales.
Pfizer's Xeljanz is an obvious beneficiary of Eli Lilly's surprise Olumiant (baricitinib) rejection at the FDA. But AbbVie and Gilead could gain, too.
Eli Lilly and partner Incyte have received a complete response letter for their highly anticipated rheumatoid arthritis drug baricitinib.
A new head-to-head study pitting Pfizer's Xeljanz against AbbVie behemoth Humira isn't going to help Pfizer as much as it had hoped.
Only 22 meds were greenlighted by the FDA in 2016, but no matter what tally the industry amasses this year, the crop will bring some would-be blockbusters and market disrupters.
Sanofi CEO Olivier Brandicourt believes the French drugmaker has fixed the issues at a fill/finish plant in France that led it and partner Regeneron to get a complete response letter for experimental rheumatoid arthritis drug sarilumab and that they should be back on track with their application this quarter.
Just yesterday, one of the biggest potential threats to Johnson & Johnson’s top line moved closer to reality as Pfizer announced it will begin shipping a biosimilar version of J&J’s blockbuster Remicade in late November. But executives of J&J, who had been insisting they wouldn’t face biosimilar competition this year, weren’t fazed during the company’s third-quarter earnings release.